[
  {
    "ts": null,
    "headline": "Franklin Biotechnology Discovery Fund Q2 2025 Commentary",
    "summary": "Franklin Templetonâs Biotechnology Discovery Fund sees long-term potential despite Q2 losses. Explore how innovation and AI are shaping its outlook.",
    "url": "https://finnhub.io/api/news?id=d61632bb7ac932a66ab21f6c57260f4bb79e88518f44428ce4f279a1392e761e",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1753997700,
      "headline": "Franklin Biotechnology Discovery Fund Q2 2025 Commentary",
      "id": 136159393,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1408826216/image_1408826216.jpg?io=getty-c-w1536",
      "related": "LLY",
      "source": "SeekingAlpha",
      "summary": "Franklin Templetonâs Biotechnology Discovery Fund sees long-term potential despite Q2 losses. Explore how innovation and AI are shaping its outlook.",
      "url": "https://finnhub.io/api/news?id=d61632bb7ac932a66ab21f6c57260f4bb79e88518f44428ce4f279a1392e761e"
    }
  },
  {
    "ts": null,
    "headline": "Stock Market Today: Indexes Trim Gains, Copper Plunges Again; Meta, Carvana Build Alternate Entries (Live Coverage)",
    "summary": "The Dow Jones index rose Thursday as it appeared a China trade deal was near. Nvidia partner Arm plunged on earnings.",
    "url": "https://finnhub.io/api/news?id=15273a4349d44a1fd9f5575c956fee9564fa0e77519464a9cf25d343b8a2a1df",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1753979467,
      "headline": "Stock Market Today: Indexes Trim Gains, Copper Plunges Again; Meta, Carvana Build Alternate Entries (Live Coverage)",
      "id": 136154955,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "The Dow Jones index rose Thursday as it appeared a China trade deal was near. Nvidia partner Arm plunged on earnings.",
      "url": "https://finnhub.io/api/news?id=15273a4349d44a1fd9f5575c956fee9564fa0e77519464a9cf25d343b8a2a1df"
    }
  },
  {
    "ts": null,
    "headline": "What Trump's Big Pharma CEO letters mean for drug pricing power",
    "summary": "President Trump is turning up the heat on Big Pharma, sending letters to 17 major drugmakers demanding lower prices across their entire portfolios. Yahoo Finance Senior Reporter Anjalee Khemlani joins Market Domination to explain how the administration is pushing for most-favored-nation pricing and giving companies until September 29 to comply. To watch more expert insights and analysis on the latest market action, check out more Market Domination.",
    "url": "https://finnhub.io/api/news?id=4833e7f299553f7689706923f0de2bea0e4ca660804c1eee2c139edccb399c18",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1753992991,
      "headline": "What Trump's Big Pharma CEO letters mean for drug pricing power",
      "id": 136160870,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "President Trump is turning up the heat on Big Pharma, sending letters to 17 major drugmakers demanding lower prices across their entire portfolios. Yahoo Finance Senior Reporter Anjalee Khemlani joins Market Domination to explain how the administration is pushing for most-favored-nation pricing and giving companies until September 29 to comply. To watch more expert insights and analysis on the latest market action, check out more Market Domination.",
      "url": "https://finnhub.io/api/news?id=4833e7f299553f7689706923f0de2bea0e4ca660804c1eee2c139edccb399c18"
    }
  },
  {
    "ts": null,
    "headline": "Eli Lilly and Company (LLY): We Sold Some Lilly, Says Jim Cramer",
    "summary": "We recently published 12 Stocks Jim Cramer Recently Discussed As He Commented On A “Sea Of Green”. Eli Lilly and Company (NYSE:LLY) is one of the stocks Jim Cramer recently discussed. Weight loss drug giant Eli Lilly and Company (NYSE:LLY)’s shares have struggled in 2025 as they have lost 2.3% year-to-date. Yet, despite the stock’s […]",
    "url": "https://finnhub.io/api/news?id=78e32c638620e5bcfba032443c837bbeb4074b18e64369dd2d45f414b3472b2b",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1753991690,
      "headline": "Eli Lilly and Company (LLY): We Sold Some Lilly, Says Jim Cramer",
      "id": 136160871,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "We recently published 12 Stocks Jim Cramer Recently Discussed As He Commented On A “Sea Of Green”. Eli Lilly and Company (NYSE:LLY) is one of the stocks Jim Cramer recently discussed. Weight loss drug giant Eli Lilly and Company (NYSE:LLY)’s shares have struggled in 2025 as they have lost 2.3% year-to-date. Yet, despite the stock’s […]",
      "url": "https://finnhub.io/api/news?id=78e32c638620e5bcfba032443c837bbeb4074b18e64369dd2d45f414b3472b2b"
    }
  },
  {
    "ts": null,
    "headline": "Trump sends letters to pharma CEOs demanding they reduce drug prices in 60 days",
    "summary": "President Trump sent letters to 17 CEOs of drug companies to force them to reduce prices within 60 days.",
    "url": "https://finnhub.io/api/news?id=a4d1603df39e6d5c3d6208cb4aa5419cb3cf80daa0a6805899a1ecb7c4dee65f",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1753990810,
      "headline": "Trump sends letters to pharma CEOs demanding they reduce drug prices in 60 days",
      "id": 136160872,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "President Trump sent letters to 17 CEOs of drug companies to force them to reduce prices within 60 days.",
      "url": "https://finnhub.io/api/news?id=a4d1603df39e6d5c3d6208cb4aa5419cb3cf80daa0a6805899a1ecb7c4dee65f"
    }
  },
  {
    "ts": null,
    "headline": "Trump Sends Letters to 17 Pharmaceutical Companies Asking Them to Lower Costs",
    "summary": "President Trump sent letters to 17 pharmaceutical companies on Thursday asking them to lower costs of drugs for U.S. consumers to the lowest price offered in other developed nations, following up on an executive order issued in May.",
    "url": "https://finnhub.io/api/news?id=6c9fe155402ddc330d8fc8a3f0a9c10084ffc5e5c1b09cdba3c34ed81efc1a64",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1753986626,
      "headline": "Trump Sends Letters to 17 Pharmaceutical Companies Asking Them to Lower Costs",
      "id": 136160873,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "President Trump sent letters to 17 pharmaceutical companies on Thursday asking them to lower costs of drugs for U.S. consumers to the lowest price offered in other developed nations, following up on an executive order issued in May.",
      "url": "https://finnhub.io/api/news?id=6c9fe155402ddc330d8fc8a3f0a9c10084ffc5e5c1b09cdba3c34ed81efc1a64"
    }
  },
  {
    "ts": null,
    "headline": "Trump pressures 17 pharma CEOs to cut US drug prices",
    "summary": "WASHINGTON (Reuters) -President Donald Trump sent letters to the leaders of 17 major pharmaceutical companies outlining how they should slash U.S. prescription drug prices to match those paid overseas, the White House said on Thursday.  Trump signed a sweeping executive order in May demanding drugmakers cut U.S. medicine prices to match those abroad, saying that if companies did not comply, the government could use rulemaking to bring prices down or pursue other measures, such as importing cheaper medicines from overseas.  Trump sent the letters to the chief executives of Eli Lilly, Sanofi, Regeneron, Merck & Co, Johnson & Johnson, and AstraZeneca, among others, the White House said.",
    "url": "https://finnhub.io/api/news?id=42f946e05257529f3d2dad4cf4341c0643378e0fd5f4f914bc3d4cd3e3e1295a",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1753986479,
      "headline": "Trump pressures 17 pharma CEOs to cut US drug prices",
      "id": 136160874,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "WASHINGTON (Reuters) -President Donald Trump sent letters to the leaders of 17 major pharmaceutical companies outlining how they should slash U.S. prescription drug prices to match those paid overseas, the White House said on Thursday.  Trump signed a sweeping executive order in May demanding drugmakers cut U.S. medicine prices to match those abroad, saying that if companies did not comply, the government could use rulemaking to bring prices down or pursue other measures, such as importing cheaper medicines from overseas.  Trump sent the letters to the chief executives of Eli Lilly, Sanofi, Regeneron, Merck & Co, Johnson & Johnson, and AstraZeneca, among others, the White House said.",
      "url": "https://finnhub.io/api/news?id=42f946e05257529f3d2dad4cf4341c0643378e0fd5f4f914bc3d4cd3e3e1295a"
    }
  },
  {
    "ts": null,
    "headline": "Trump demands largest pharma companies slash US drug prices",
    "summary": "(Bloomberg) -- President Donald Trump sent letters to 17 of the world’s largest pharmaceutical companies — including Eli Lilly & Co., Novo Nordisk A/S and Pfizer Inc. — insisting they slash their US prices on new drugs to the lowest amount paid by certain other countries.Most Read from BloombergThe World’s Data Center Capital Has Residents SurroundedAn Abandoned Art-Deco Landmark in Buffalo Awaits RevivalWe Should All Be Biking Along the BeachBudapest’s Most Historic Site Gets a Controversial Re",
    "url": "https://finnhub.io/api/news?id=292aa5d0e8c41af62ddead7ad247376e84410f5a02b83d2a1a0bbf469f796efb",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1753985112,
      "headline": "Trump demands largest pharma companies slash US drug prices",
      "id": 136160875,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "(Bloomberg) -- President Donald Trump sent letters to 17 of the world’s largest pharmaceutical companies — including Eli Lilly & Co., Novo Nordisk A/S and Pfizer Inc. — insisting they slash their US prices on new drugs to the lowest amount paid by certain other countries.Most Read from BloombergThe World’s Data Center Capital Has Residents SurroundedAn Abandoned Art-Deco Landmark in Buffalo Awaits RevivalWe Should All Be Biking Along the BeachBudapest’s Most Historic Site Gets a Controversial Re",
      "url": "https://finnhub.io/api/news?id=292aa5d0e8c41af62ddead7ad247376e84410f5a02b83d2a1a0bbf469f796efb"
    }
  },
  {
    "ts": null,
    "headline": "Novo Nordisk’s Weight Loss Lesson",
    "summary": "Novo Nordisk’s Weight Loss Lesson",
    "url": "https://finnhub.io/api/news?id=ba71cda4abe13d691ae2098407b34db43c1f22a002d8e99db0eee822b60f9c11",
    "source": "DowJones",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1753984800,
      "headline": "Novo Nordisk’s Weight Loss Lesson",
      "id": 136167582,
      "image": "",
      "related": "LLY",
      "source": "DowJones",
      "summary": "Novo Nordisk’s Weight Loss Lesson",
      "url": "https://finnhub.io/api/news?id=ba71cda4abe13d691ae2098407b34db43c1f22a002d8e99db0eee822b60f9c11"
    }
  },
  {
    "ts": null,
    "headline": "Eli Lilly (LLY) Reveals Promising Diabetes and Alzheimer's Trials Results",
    "summary": "Eli Lilly (LLY) has recently shared positive developments in its innovative therapies, reporting significant progress with Mounjaro and Kisunla in cardiovascular health and Alzheimer's treatment, respectively. Over the past month, LLY experienced a 2.5% decline in its stock price, slightly diverging from broader market trends where major indexes were generally buoyed by strong earnings from tech giants like Microsoft and Meta. While Eli Lilly's advancements in clinical trials and strategic...",
    "url": "https://finnhub.io/api/news?id=43f35e65f9e32291f7407dbf9092e4d017018be2561b238728eb3144dbcd827f",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1753983633,
      "headline": "Eli Lilly (LLY) Reveals Promising Diabetes and Alzheimer's Trials Results",
      "id": 136160876,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Eli Lilly (LLY) has recently shared positive developments in its innovative therapies, reporting significant progress with Mounjaro and Kisunla in cardiovascular health and Alzheimer's treatment, respectively. Over the past month, LLY experienced a 2.5% decline in its stock price, slightly diverging from broader market trends where major indexes were generally buoyed by strong earnings from tech giants like Microsoft and Meta. While Eli Lilly's advancements in clinical trials and strategic...",
      "url": "https://finnhub.io/api/news?id=43f35e65f9e32291f7407dbf9092e4d017018be2561b238728eb3144dbcd827f"
    }
  },
  {
    "ts": null,
    "headline": "Targeting energy expenditure: the next wave of obesity drugs",
    "summary": "Biotechs investigate mitochondria-targeting drugs to claim a share in the weight loss drug market dominated by GLP-1RAs.",
    "url": "https://finnhub.io/api/news?id=40c4d8d61cc102d0a7e3b4652c316ec22a6b5955a03a9d6f3e17d4acaaade7ea",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1753983071,
      "headline": "Targeting energy expenditure: the next wave of obesity drugs",
      "id": 136160877,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Biotechs investigate mitochondria-targeting drugs to claim a share in the weight loss drug market dominated by GLP-1RAs.",
      "url": "https://finnhub.io/api/news?id=40c4d8d61cc102d0a7e3b4652c316ec22a6b5955a03a9d6f3e17d4acaaade7ea"
    }
  },
  {
    "ts": null,
    "headline": "Stock Market Today: Indexes Swing Lower While Amazon Rises Ahead Of Earnings; Apple Fades; IPO Figma Soars 277%",
    "summary": "Stock Market Today: Indexes Swing Lower While Amazon Rises Ahead Of Earnings; Apple Fades; IPO Figma Soars 277%",
    "url": "https://finnhub.io/api/news?id=bd379c07e6045494ff5863feb7277544e2fc18f155bc55b7c7517527d87df619",
    "source": "DowJones",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1753980668,
      "headline": "Stock Market Today: Indexes Swing Lower While Amazon Rises Ahead Of Earnings; Apple Fades; IPO Figma Soars 277%",
      "id": 136167584,
      "image": "",
      "related": "LLY",
      "source": "DowJones",
      "summary": "Stock Market Today: Indexes Swing Lower While Amazon Rises Ahead Of Earnings; Apple Fades; IPO Figma Soars 277%",
      "url": "https://finnhub.io/api/news?id=bd379c07e6045494ff5863feb7277544e2fc18f155bc55b7c7517527d87df619"
    }
  },
  {
    "ts": null,
    "headline": "Eli Lilly Weight-Loss Drug Makes Cardio Advance. More Bad News for Novo Nordisk.",
    "summary": "A Lilly study showed Mounjaro resulted in a lower risk of heart attacks and strokes in patients with diabetes compared with the older drug Trulicity.",
    "url": "https://finnhub.io/api/news?id=af0368ea155675b8c06f056d2f64de56599eb28452b8c7d28e37872375aad5ae",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1753971120,
      "headline": "Eli Lilly Weight-Loss Drug Makes Cardio Advance. More Bad News for Novo Nordisk.",
      "id": 136154332,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "A Lilly study showed Mounjaro resulted in a lower risk of heart attacks and strokes in patients with diabetes compared with the older drug Trulicity.",
      "url": "https://finnhub.io/api/news?id=af0368ea155675b8c06f056d2f64de56599eb28452b8c7d28e37872375aad5ae"
    }
  },
  {
    "ts": null,
    "headline": "Eli Lilly (LLY) Reports Next Week: Wall Street Expects Earnings Growth",
    "summary": "Lilly (LLY) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.",
    "url": "https://finnhub.io/api/news?id=44247ebe19dea9f5a0c21858a137dc32ed132fbc81d573c575182eef76c1c4a8",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1753970424,
      "headline": "Eli Lilly (LLY) Reports Next Week: Wall Street Expects Earnings Growth",
      "id": 136155098,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Lilly (LLY) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.",
      "url": "https://finnhub.io/api/news?id=44247ebe19dea9f5a0c21858a137dc32ed132fbc81d573c575182eef76c1c4a8"
    }
  },
  {
    "ts": null,
    "headline": "Eli Lilly’s stock drops as Trump targets 17 drug makers with letters on their pricing",
    "summary": "Eli Lilly’s stock drops as Trump targets 17 drug makers with letters on their pricing",
    "url": "https://finnhub.io/api/news?id=ee25f6a7ccf490a1c8ac7a7c36dbd53233365d252df20a9a81eca58f039ed2f5",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1753970004,
      "headline": "Eli Lilly’s stock drops as Trump targets 17 drug makers with letters on their pricing",
      "id": 136167611,
      "image": "",
      "related": "LLY",
      "source": "MarketWatch",
      "summary": "Eli Lilly’s stock drops as Trump targets 17 drug makers with letters on their pricing",
      "url": "https://finnhub.io/api/news?id=ee25f6a7ccf490a1c8ac7a7c36dbd53233365d252df20a9a81eca58f039ed2f5"
    }
  },
  {
    "ts": null,
    "headline": "What Makes Eli Lilly and Company (LLY) a Lucrative Investment?",
    "summary": "Baron Funds, an investment management company, released its “Baron Health Care Fund” second-quarter 2025 investor letter. A copy of the letter can be downloaded here. The fund declined 5.06% (Institutional Shares) in the quarter, against a challenging backdrop for the broader Health Care sector, compared to a 6.19% decline for the Russell 3000 Health Care […]",
    "url": "https://finnhub.io/api/news?id=4292323a5153fc7f49f1e3733ba004545d5a8970012e315e1fa16e6b621009ce",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1753966555,
      "headline": "What Makes Eli Lilly and Company (LLY) a Lucrative Investment?",
      "id": 136151735,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Baron Funds, an investment management company, released its “Baron Health Care Fund” second-quarter 2025 investor letter. A copy of the letter can be downloaded here. The fund declined 5.06% (Institutional Shares) in the quarter, against a challenging backdrop for the broader Health Care sector, compared to a 6.19% decline for the Russell 3000 Health Care […]",
      "url": "https://finnhub.io/api/news?id=4292323a5153fc7f49f1e3733ba004545d5a8970012e315e1fa16e6b621009ce"
    }
  },
  {
    "ts": null,
    "headline": "Elli Lilly Weight-Loss Drug Makes Cardio Advance. More Bad News for Novo Nordisk.",
    "summary": "A Lilly study showed Mounjaro resulted in a lower risk of heart attacks and strokes in patients with diabetes compared with the older drug Trulicity.",
    "url": "https://finnhub.io/api/news?id=933f27a92809c6dbceb4f9f147101aab80edfb3c039ad2bacdbda27e9276103c",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1753965180,
      "headline": "Elli Lilly Weight-Loss Drug Makes Cardio Advance. More Bad News for Novo Nordisk.",
      "id": 136151736,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "A Lilly study showed Mounjaro resulted in a lower risk of heart attacks and strokes in patients with diabetes compared with the older drug Trulicity.",
      "url": "https://finnhub.io/api/news?id=933f27a92809c6dbceb4f9f147101aab80edfb3c039ad2bacdbda27e9276103c"
    }
  },
  {
    "ts": null,
    "headline": "Lilly stock falls as Mounjaro fails to show superiority over Trulicity",
    "summary": "Investing.com -- Eli Lilly and Company (NYSE:LLY) stock fell on Thursday morning after the pharmaceutical giant’s diabetes drug Mounjaro failed to demonstrate superiority over its older GLP-1 drug Trulicity in a cardiovascular outcomes trial.",
    "url": "https://finnhub.io/api/news?id=8d2b0f5065dc0be0f330e63912f7eb586b7d40e2ffafbc1ad9c7a11f94b5776a",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1753964050,
      "headline": "Lilly stock falls as Mounjaro fails to show superiority over Trulicity",
      "id": 136151738,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Investing.com -- Eli Lilly and Company (NYSE:LLY) stock fell on Thursday morning after the pharmaceutical giant’s diabetes drug Mounjaro failed to demonstrate superiority over its older GLP-1 drug Trulicity in a cardiovascular outcomes trial.",
      "url": "https://finnhub.io/api/news?id=8d2b0f5065dc0be0f330e63912f7eb586b7d40e2ffafbc1ad9c7a11f94b5776a"
    }
  },
  {
    "ts": null,
    "headline": "Biogen lifts full-year outlook amid Alzheimer’s drug strength, sending shares up",
    "summary": "Investing.com - Shares of Biogen (NASDAQ:BIIB) rose in premarket U.S. trading on Thursday after the drugmaker posted better-than-anticipated first-quarter revenue and raised its full-year guidance thanks in part to solid sales of its Alzheimer’s drug.",
    "url": "https://finnhub.io/api/news?id=f18520da70879589b802b7b5b1c42c6c48b98fa3a55d78a5a145c60a9a3ecb5b",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1753958974,
      "headline": "Biogen lifts full-year outlook amid Alzheimer’s drug strength, sending shares up",
      "id": 136151739,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Investing.com - Shares of Biogen (NASDAQ:BIIB) rose in premarket U.S. trading on Thursday after the drugmaker posted better-than-anticipated first-quarter revenue and raised its full-year guidance thanks in part to solid sales of its Alzheimer’s drug.",
      "url": "https://finnhub.io/api/news?id=f18520da70879589b802b7b5b1c42c6c48b98fa3a55d78a5a145c60a9a3ecb5b"
    }
  },
  {
    "ts": null,
    "headline": "Lilly's Mounjaro (tirzepatide), a GIP/GLP-1 dual agonist, demonstrated cardiovascular protection in landmark head-to-head trial, reinforcing its benefit in patients with type 2 diabetes and heart disease",
    "summary": "Eli Lilly and Company (NYSE: LLY) today announced topline results from SURPASS-CVOT, a first-of-its-kind head-to-head Phase 3 cardiovascular outcomes trial comparing two incretin therapies in adults with type 2 diabetes and established atherosclerotic cardiovascular disease. Mounjaro (tirzepatide), a GIP/GLP-1 dual receptor agonist, was compared to Trulicity (dulaglutide), a GLP-1 receptor agonist that showed a definitive cardiovascular benefit in the REWIND study. In SURPASS-CVOT, Mounjaro achi",
    "url": "https://finnhub.io/api/news?id=309ea94e7476776af877662d0480ee7ddce3c4aeac4106326f8f65f22fae982c",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1753958700,
      "headline": "Lilly's Mounjaro (tirzepatide), a GIP/GLP-1 dual agonist, demonstrated cardiovascular protection in landmark head-to-head trial, reinforcing its benefit in patients with type 2 diabetes and heart disease",
      "id": 136151741,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Eli Lilly and Company (NYSE: LLY) today announced topline results from SURPASS-CVOT, a first-of-its-kind head-to-head Phase 3 cardiovascular outcomes trial comparing two incretin therapies in adults with type 2 diabetes and established atherosclerotic cardiovascular disease. Mounjaro (tirzepatide), a GIP/GLP-1 dual receptor agonist, was compared to Trulicity (dulaglutide), a GLP-1 receptor agonist that showed a definitive cardiovascular benefit in the REWIND study. In SURPASS-CVOT, Mounjaro achi",
      "url": "https://finnhub.io/api/news?id=309ea94e7476776af877662d0480ee7ddce3c4aeac4106326f8f65f22fae982c"
    }
  },
  {
    "ts": null,
    "headline": "10 stocks favored to gain up to 30% in a sector that has missed this year’s rally",
    "summary": "10 stocks favored to gain up to 30% in a sector that has missed this year’s rally",
    "url": "https://finnhub.io/api/news?id=a3d55fc62adc0e6275a55a4f77c3dca1b37f39555b23e563d9785d4fca06fe3e",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1753955520,
      "headline": "10 stocks favored to gain up to 30% in a sector that has missed this year’s rally",
      "id": 136167613,
      "image": "",
      "related": "LLY",
      "source": "MarketWatch",
      "summary": "10 stocks favored to gain up to 30% in a sector that has missed this year’s rally",
      "url": "https://finnhub.io/api/news?id=a3d55fc62adc0e6275a55a4f77c3dca1b37f39555b23e563d9785d4fca06fe3e"
    }
  },
  {
    "ts": null,
    "headline": "Eli Lilly and Biogen/Eisai’s extension trials make waves in Alzheimer’s market",
    "summary": "Lilly’s Kisunla and Biogen/Eisai’s Leqembi can both continue to slow Alzheimer's cognitive decline after more than three years of treatment.",
    "url": "https://finnhub.io/api/news?id=979a404dd6a10337e723698ffbb68fd75c0cc8eaceb32a3a7ef71282ba99f2dc",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1753953641,
      "headline": "Eli Lilly and Biogen/Eisai’s extension trials make waves in Alzheimer’s market",
      "id": 136151742,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Lilly’s Kisunla and Biogen/Eisai’s Leqembi can both continue to slow Alzheimer's cognitive decline after more than three years of treatment.",
      "url": "https://finnhub.io/api/news?id=979a404dd6a10337e723698ffbb68fd75c0cc8eaceb32a3a7ef71282ba99f2dc"
    }
  },
  {
    "ts": null,
    "headline": "Losses for health care stocks help push Wall Street lower",
    "summary": "Stocks capped a choppy day of trading on Wall Street with more losses Thursday after an early big tech rally faded and a health care sector pullback led the market lower.  The benchmark index, which is just below the record high it set on Monday, notched a 2.2% gain for the month of July and is up 7.8% so far this year.  The Dow Jones Industrial Average lost 0.7%, and the Nasdaq composite closed less than 0.1% lower.",
    "url": "https://finnhub.io/api/news?id=1302d6adbadb6a9f06505601bf9d9d413408e94e945c9029646a5efc11eedec4",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1753936315,
      "headline": "Losses for health care stocks help push Wall Street lower",
      "id": 136160878,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Stocks capped a choppy day of trading on Wall Street with more losses Thursday after an early big tech rally faded and a health care sector pullback led the market lower.  The benchmark index, which is just below the record high it set on Monday, notched a 2.2% gain for the month of July and is up 7.8% so far this year.  The Dow Jones Industrial Average lost 0.7%, and the Nasdaq composite closed less than 0.1% lower.",
      "url": "https://finnhub.io/api/news?id=1302d6adbadb6a9f06505601bf9d9d413408e94e945c9029646a5efc11eedec4"
    }
  }
]